Super Elongation Complex Disruptors for Cancer Therapeutics

Project: Research project

Project Details


Goal of the Project
Generate a data package that will support the advancement of a molecule derived from the current lead series of Super Elongation Complex Disruptors (SEC-KL) into an oncology clinical study by April 15, 2023, or a suitable alternate molecule or back-up (SEC-BU) by April 15, 2024 and/or the licensing of the intellectual property associated with this collaboration project to a third party by April 15, 2024.
Target Product Profile
The project aims to develop a medicinal therapy that will:
• Disrupt oncogenic transcriptional programming
• Reduce/eliminate tumor cell proliferation
• Improve survival outcome for patients
Effective start/end date4/15/194/14/24


  • Lakeside Discovery, LLC (Agmt 5/18/18)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.